Mediwound Ltd (MDWD) Issues Quarterly Earnings Results

Mediwound Ltd (NASDAQ:MDWD) posted its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.17) by $0.03. Mediwound had a negative return on equity of 148.23% and a negative net margin of 1,776.06%. The firm had revenue of $0.54 million for the quarter, compared to analysts’ expectations of $0.56 million. During the same period last year, the business earned ($0.17) earnings per share. The firm’s revenue for the quarter was up 112.6% on a year-over-year basis.

Mediwound (NASDAQ:MDWD) traded down 0.74% during mid-day trading on Friday, reaching $6.75. The company’s stock had a trading volume of 3,606 shares. The stock’s market cap is $148.03 million. The company has a 50 day moving average of $6.41 and a 200-day moving average of $5.81. Mediwound has a 52-week low of $4.25 and a 52-week high of $8.58.

Earnings History for Mediwound (NASDAQ:MDWD)

A number of research analysts have recently commented on the company. Oppenheimer Holdings Inc. set a $10.00 price objective on Mediwound and gave the company a “buy” rating in a report on Monday, May 8th. Zacks Investment Research lowered Mediwound from a “hold” rating to a “sell” rating in a report on Tuesday, February 21st. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $10.75.

TRADEMARK VIOLATION WARNING: “Mediwound Ltd (MDWD) Issues Quarterly Earnings Results” was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://www.chaffeybreeze.com/2017/05/19/mediwound-ltd-mdwd-releases-quarterly-earnings-results-misses-estimates-by-0-03-eps-updated.html.

Large investors have recently bought and sold shares of the company. Renaissance Technologies LLC raised its position in Mediwound by 1.7% in the first quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock worth $499,000 after buying an additional 1,300 shares in the last quarter. Citadel Advisors LLC raised its position in Mediwound by 4.5% in the third quarter. Citadel Advisors LLC now owns 33,622 shares of the biopharmaceutical company’s stock worth $259,000 after buying an additional 1,456 shares during the period. Wells Fargo & Company MN raised its position in Mediwound by 19.7% in the first quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 8,745 shares during the period. Broadfin Capital LLC raised its position in Mediwound by 19.2% in the fourth quarter. Broadfin Capital LLC now owns 633,102 shares of the biopharmaceutical company’s stock worth $2,899,000 after buying an additional 102,117 shares during the period. Finally, Wellington Management Group LLP raised its position in Mediwound by 11.0% in the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock worth $14,241,000 after buying an additional 213,745 shares during the period. 27.49% of the stock is currently owned by institutional investors.

Mediwound Company Profile

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

5 Day Chart for NASDAQ:MDWD

Receive News & Ratings for Mediwound Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply